Drugs Made In America Acq... (DMAA)
NASDAQ: DMAA
· Real-Time Price · USD
10.12
-0.01 (-0.10%)
At close: May 23, 2025, 3:59 PM
10.35
2.27%
After-hours: May 23, 2025, 07:51 PM EDT
Company Description
Drugs Made In America Acquisition Corp. operates as a blank check company.
The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Drugs Made In America Acquisition Corp. Ordinary Shares
| Country | United States |
| IPO Date | n/a |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | n/a |
| CEO | Lynn Stockwell |
Contact Details
Address: 1 East Broward Blvd Suite 700 Fort Lauderdale, Florida United States | |
| Website | https://dmaacorp.com |
Stock Details
| Ticker Symbol | DMAA |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0002028614 |
| CUSIP Number | n/a |
| ISIN Number | KYG2847J1040 |
| Employer ID | 00-0000000 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Lynn Stockwell | Chief Executive Officer & Executive Chairman |
| Glenn Charles Worman | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 20, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 15, 2025 | NT 10-Q | Filing |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | SCHEDULE 13G | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 03, 2025 | SCHEDULE 13D | Filing |
| Feb 25, 2025 | 8-K | Current Report |